Stock TKDA TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Market Closed - Deutsche Boerse AG
Other stock markets
 02:04:07 2024-06-21 EDT 		5-day change 1st Jan Change
11.6 EUR 0.00% Intraday chart for Takeda Pharmaceutical Company Limited -3.33% -7.94%
04:30am Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia CI
06-21 Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.3 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
-7.94% 39.61B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 628B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 228B
A+
NOVARTIS AG Stock Novartis AG
+10.75% 214B
B-
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TKDA Stock
  5. Ratings Takeda Pharmaceutical Company Limited